All of these mechanisms of action translated into excellent tumor growth inhibition effects in vivo, as observed in a panel of NSCLC xenograft models with diverse receptor density and EGFR and kRAS mutation status (Figure 4; Supplementary Table 1; Supplementary Figure S4). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.